RT Journal Article
SR Electronic
T1 A Genome-Wide Association Study Reveals Novel Genetic Markers Associated with Human African Trypanosomiasis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.14.24307227
DO 10.1101/2024.05.14.24307227
A1 Mulindwa, Julius
A1 Kimuda, Magambo Phillip
A1 Noyes, Harry
A1 Ilboudo, Hamidou
A1 Koffi, Mathurin
A1 Ahouty, Bernadin
A1 Nyangiri, Oscar
A1 Cooper, Anneli
A1 Clucas, Caroline
A1 Nambala, Peter
A1 Musaya, Janelisa
A1 Ngoyi, Dieudonne ́ Mumba
A1 Karume, Kevin
A1 Fataki, Olivier
A1 Simo, Gustave
A1 Ofon, Elvis
A1 Enyaru, John
A1 Nerima, Barbara
A1 Tait, Andy
A1 Marcello, Lucio
A1 Chisi, John
A1 Kabore, Jacques
A1 Kabore, Justin Windingoudi
A1 Kamoto, Kelita
A1 Simuunza, Martin
A1 Alibu, Vincent P.
A1 Jamonneau, Vincent
A1 Camera, Marianne
A1 Camara, Mamadou
A1 Bucheton, Bruno
A1 Hertz-Fowler, Christiane
A1 Macleod, Annette
A1 Matovu, Enock
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/05/15/2024.05.14.24307227.abstract
AB Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense cause human African trypanosomiasis (HAT), a neglected tropical disease that constitutes an important public health issue in sub-Saharan Africa. In the absence of a vaccine, only chemotherapy and vector control has been used to combat the disease. Environmental factors, such as exposure to infected tsetse files, and genetic factors such as variants in the APOL1 gene have been shown to contribute to the risk of developing HAT. However, the known factors only explain a small part of the risk of developing trypanosomiasis. We have undertaken a genome wide association study (GWAS) using 3813 samples from T. b. gambiense and T.b. rhodesiense HAT foci in Guinea, Côte d’Ivoire, Cameroon, DRC, Malawi and Uganda. 2141 samples were genotyped on the H3Africa SNP chip followed by a genotyping a validation cohort of an additional 1,627 samples at candidate loci. After the primary and validation studies we identified a novel locus near SMOC2 with genome-wide significance. We also identified suggestive associations near NXN, NTNG1 and NCKAP5 that have stronger associations with disease susceptibility than the APOL1 loci that has been previously identified by hypothesis driven approaches. These genes offer new entry points for future studies of the underlying genetic mechanisms of HAT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Human Heredity and Health in Africa (H3Africa) programme under Wellcome Trust grant number 099310/Z/12/Z and H3Africa grant number H3A-18- 004. H3Africa is managed by the Science for Africa Foundation (SFA Foundation) in partnership with Wellcome, NIH and AfSHG. The views expressed herein are those of the author(s) and not necessarily those of the SFA Foundation and her partners.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Minister de la Sante Publique (Democratic Republic of Congo) gave ethical approval for this work No 1/2013; Ministere de la Sante et de la Lutte Contre le SIDA of Cote d'Ivoıre gave ethical approval for this work; Uganda Vector Control Division Research Ethics Committee (Ministry of Health), gave ethical approval for this work ; Uganda National Council for Science and Technology HS 1344 gave ethical approval for this work; Comite Consultatif de Deontologie et d'Ethique [CCDE] de l'Institut de Recherche pour le Developpement: gave ethical approval for this work; 1-22/04/2013; Cameroon (Le Comite National d'Ethique de la Recherche pour la Sante Humain: 2013/364/L/CNERSH/ SP), Comite National D'Ethique et de la Recherche 2014/No 38/ MSLS/CNER-dkn) gave ethical approval for this work Malawi National Health Sciences Research Committee, protocol numbers NHSRC15/4/1399 and Malawi 1213 gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors